Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Scrip

Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

By Scrip Team 18 Jan 2022

More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.

Scrip

Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

By Joseph Haas 17 Jan 2022

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 17 Jan 2022

In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

Scrip

A Deep Dive Into The Game-Changing Drugs For Skin Diseases

By Scrip Team 17 Jan 2022

Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

Pharma Intelligence Apps

Straight Talk on Clinical Trials: Informa Pharma Intelligence and Rare Patient Voice

12 Jan 2022

Date: Wednesday, Feb. 16 Time: noon ET Register .hero-banner .content{ width: 100%; }

Scrip

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

By Alaric DeArment 10 Jan 2022

CancerCells_Creations_223873720_1200x675

At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 10 Jan 2022

In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

Pharma Intelligence Apps

Not all news services are created equal

06 Jan 2022

Pharma Insights team of trusted journalists bring you the most critical news and analysis round the clock. Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments. Register for your free trial today to find out what our editors and journalists are reporting on now.

Scrip

BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA

By Alaric DeArment 05 Jan 2022

RandDsign_PanchenkoVladimir_507673309_1200x675

The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.

Scrip

Five (Non-COVID) Clinical Trial Misses Of 2021

By Alex Shimmings 04 Jan 2022

The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.

Scrip

MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’

By Andrew McConaghie 23 Dec 2021

MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.

Scrip

Ocugen CEO Musunuri On Gene Therapy Candidates, The Omicron Advantage

By Vibha Ravi 22 Dec 2021

Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.

Scrip

APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong

By Ian Haydock 01 Dec 2021

Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.

Scrip

COVID-19 Vaccine Makers Pledge Rapid Response To Omicron Threat

By Andrew McConaghie 29 Nov 2021

While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 28 Nov 2021

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.